Cerus Corp - $CERS STOCK NEWS

Cerus (Nasdaq: CERS) will release its first quarter 2024 financial results on May 2, 2024. The company will host a conference call and webcast to discuss the financial results and provide a business outlook.

Cerus (CERS) receives FDA approval for a 12-month shelf life extension for INTERCEPT Platelet Processing Sets, providing relief to customers and supply chains. The company aims to pursue further extensions beyond 12 months.

Cerus (Nasdaq: CERS) announces positive results for ReCePI Phase 3 trial of INTERCEPT Red Blood Cells showing non-inferiority in acute kidney injury incidence compared to conventional RBCs. Safety data also favorable.

Cerus Corporation (Nasdaq: CERS) reported sequential revenue growth in the fourth quarter driven by sales in North America, with a narrowed GAAP net loss. The company achieved its goal of adjusted EBITDA breakeven for the fourth quarter and reiterated its full-year 2024 product revenue guidance range of $172-175 million. Cash and cash equivalents were $65.9 million at the end of December 2023.

Cerus Corporation (CERS) will release its fourth quarter and full-year 2023 financial results on March 5, 2024. A conference call and webcast will follow to discuss the financial results and provide a business outlook.

Cerus Corporation (CERS) will have management participation in two upcoming investor conferences, the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13th and TD Cowen’s 44th Annual Health Care Conference on March 6th. The company will also have a live webcast of the TD Cowen presentation, with a replay available on their website after the event.

Cerus Corporation (CERS) announces preliminary fourth quarter and full-year 2023 product revenues of $46.8 million and $156.4 million, respectively. The company also provided product revenue guidance for full-year 2024, expecting revenues to be between $172-$175 million, reflecting 10%-12% growth year over year. The unaudited preliminary product revenue for the fourth quarter of 2023 showed a 6% increase over the same period in 2022, and a sequential increase of 18%. Cerus expects double-digit product revenue growth for full-year 2024, driven by continued growth in their INTERCEPT Platelet franchises in both the U.S. and internationally, as well as in the INTERCEPT Fibrinogen Complex business. The company also anticipates reaching adjusted EBITDA breakeven for the fourth quarter of 2023, which will be important for funding future growth. Additionally, Cerus anticipates a meaningful year for their INTERCEPT Red Blood Cell (RBC) program in 2024, with key catalysts for advancing the program towards commercialization expected in the first and second half of 2024.

Cerus Corporation (NASDAQ:CERS) will participate in two upcoming investor conferences. Cerus' president and CEO, William 'Obi' Greenman, will participate in a fireside chat at The Stifel 2023 Healthcare Conference on November 14th. Cerus' CFO, Kevin Green, will participate in a fireside chat at The Stephens Annual Investment Conference on November 15th.

Cerus Corporation (Nasdaq: CERS) announced Q3 2023 financial results with total revenue of $47.3 million, consisting of $39.8 million in product revenue and $7.5 million in government contract revenue. The company completed Phase 3 ReCePI study enrollment in cardiovascular surgery patients and expects top-line data readout in Q1 2024. Cash, cash equivalents, and short-term investments were $79.0 million at the end of September 2023. The company reaffirmed its commitment to achieve non-GAAP adjusted EBITDA breakeven in Q4 2023.